Valuation
- Market cap
- 18,000
- Revenue TTM
- $100,000
- Net income TTM
- $-35,350,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -35,350.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,000
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 179,348,000
- Stochastic %K
- 0%
- Beta
- 32.88
- Analysts
- —
- Price target
- —
Company profile
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate f...
Show more
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was founded in 1988 and is headquartered in Solna, Sweden.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 46 18 50 54 40
- Website
- https://www.vivesto.com
- Address
- Gustav III:s Boulevard 46, 5th floor, Solna, Sweden
Latest news
No headlines yet.
